ADMA - ADMAバイオロジックス (ADMA Biologics Inc) ADMAバイオロジックス



symbol ADMA
会社名 ADMA Biologics Inc (ADMAバイオロジックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ADMA Biologics Inc. is a late-stage biopharmaceutical company that develops manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers which includes its operations in Georgia; Research and Development which includes its plasma development operations in New Jersey and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate RI-002 is intended for the treatment of primary immune deficiency disease.   ADMA バイオロジックスは、米国のバイオ医薬品企業。特定の感染症の治療および予防のためのプラズマベ―スの生物製剤の開発、製造、売買に従事する。同社が焦点を当てる患者集団は、基礎免疫不全障害に苦しむ免疫無防備状態の患者が含まれる。主な製品候補「RI-002」は、原発性免疫不全症の治療のために投与される。   ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases.
本社所在地 465 State Route 17 Ramsey NJ 07446 USA
代表者氏名 Steven A. Elms スティーブンA.エルムズ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 201-478-5552
設立年月日 38139
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 295人
EBITDA EBITDA(百万ドル) -50.10306
終値(lastsale) 5.78
時価総額(marketcap) 267900190.92
時価総額 時価総額(百万ドル) 275.31610
売上高 売上高(百万ドル) 25.43085
企業価値(EV) 企業価値(EV)(百万ドル) 263.82142
当期純利益 当期純利益(百万ドル) -60.75549
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ADMA Biologics Inc revenues increased 44% to $8.7M. Net loss increased from $15.6M to $32.6M. Revenues reflect ADMA Bio Manufacturing segment increase from $539K to $3.8M Corporate segment remaining flat at $71K. Higher net loss reflects ADMA Bio Manufacturing segment loss increase from $3.1M to $22.6M Plasma Collection Center segment loss increase of 78% to $2M.



   ADMA Bio down 5% on pricing equity offering  2019-05-17
ADMA Biologics (NASDAQ: ADMA ) has priced its public offering of 11.25M common shares at $4.00 per share, for gross proceeds of ~$45M. More news on: ADMA Biologics, Inc., Healthcare stocks news, Stocks on the move, Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ADMAバイオロジックス ADMA ADMA Biologics Inc)

 twitter  (公式ツイッターやCEOツイッターなど)